Skip to content
Colorectal Cancer Clinical Trials

Duarte, California

Colorectal cancer clinical trials in Duarte, CA

50 colorectal cancer studies are recruiting participants at sites in Duarte as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Duarte at a glance

  • 50 studies are recruiting at a site in Duarte.
  • By phase: Phase 1 (21), Phase 1/2 (4), Phase 2 (8), Phase 2/3 (1), Phase 3 (3), No phase (3), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (30), university, hospital or other (20).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Duarte

Basic details from each study's public record (the 30 most recently updated of 50). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    City of Hope Cancer Center
    Registry record
    NCT06004245 · updated
  2. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT07503808 · updated
  3. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT04929223 · updated
  4. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  5. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    Registry record
    NCT07318805 · updated
  6. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05174169 · updated
  7. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    • Observational
    • Ages 40 and older
    • All sexes
    Sponsor
    Adela, Inc
    Study site
    City of Hope
    Registry record
    NCT05366881 · updated
  8. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    City of Hope - Duarte Cancer Center
    Registry record
    NCT06760819 · updated
  9. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    City of Hope
    Registry record
    NCT07114601 · updated
  10. Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT06130826 · updated
  11. LYL273 for Patients With Relapsed or Refractory mCRC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05319314 · updated
  12. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    City of Hope National Medical Center /ID# 270255
    Registry record
    NCT06820463 · updated
  13. Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Delcath Systems Inc.
    Study site
    City of Hope
    Registry record
    NCT06607458 · updated
  14. Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BigHat Biosciences, Inc.
    Study site
    City of Hope Duarte
    Registry record
    NCT07529808 · updated
  15. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    City of Hope National Medical Center /ID# 279449
    Registry record
    NCT07525206 · updated
  16. Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT07595874 · updated
  17. A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    City of Hope - Duarte Cancer Center
    Registry record
    NCT07535112 · updated
  18. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Dispatch Biotherapeutics
    Study site
    City of Hope
    Registry record
    NCT07544589 · updated
  19. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT06625775 · updated
  20. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated
  21. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Phanes Therapeutics
    Study site
    City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    Registry record
    NCT05482893 · updated
  22. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Study site
    City of Hope
    Registry record
    NCT07020117 · updated
  23. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    City of Hope
    Registry record
    NCT07217171 · updated
  24. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    City of Hope
    Registry record
    NCT03715933 · updated
  25. Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer

    • No phase
    • Ages 40 to 80
    • Male participants
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT07790718 · updated
  26. PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT04329494 · updated
  27. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Cartography Biosciences
    Study site
    City of Hope Duarte
    Registry record
    NCT07321106 · updated
  28. Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT07125729 · updated
  29. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  30. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    City of Hope National Medical Center
    Registry record
    NCT07094113 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Duarte, CA on ClinicalTrials.gov.

Ask about studies near Duarte

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call